Optovue announced commercial availability of AngioAnalytics, the next generation of its OCT Angiography (OCTA) technology available on the AngioVue Imaging System, for use outside of the United States, according to a company news release. This new capability enables clinicians to quantify the density of blood flow in the retina, the light-sensitive portion of the eye, to help manage diseases that cause progressive blindness such as diabetic retinopathy or acute macular degeneration.
Optovue also announced it will host an educational symposium at the World Ophthalmology Congress (WOC 2016) entitled, “The Transformative Power of Quantitative OCT Angiography” on Feb. 7. Moderated by David Huang, MD, PhD, the evening symposium will feature four industry experts who will present recent clinical findings on OCTA, the AngioVue System and AngioAnalytics.
“AngioAnalytics adds an important element to the treatment algorithm by quantifying the density of blood vessels in the eye where blood flow can be detected,” Richard Rosen, MD, FACS, FASRS, CRA, Professor of Ophthalmology and Director of Retina at the New York Eye and Ear Infirmary, said in the news release.
“Early detection of eye disease is essential for optimizing treatment, and for the first time, changes to the patient’s retinal microcirculation can be quantified using a non-invasive method. Additionally, we are able to track these changes from visit to visit to better understand the rate of disease progression and the efficacy of treatment. It is certainly feasible that this new information will change the clinical management of diabetic retinopathy, age-related macular degeneration, and other diseases that progressively rob patients of their vision,” continued Dr. Rosen.
Since its introduction, Optovue’s AngioVue System has been installed and incorporated into daily clinical use at over 500 sites outside of the United States, and is the subject of 88 peer-reviewed scientific publications.
“The availability of our breakthrough AngioAnalytics technology raises the standard of care available to patients while improving practice workflow and diagnostic confidence,” Jay Wei, founder and chief executive officer for Optovue, said in the news release. “With the addition of AngioAnalytics to the AngioVue system, clinicians now have objective data regarding the areas encompassed by flow and non-flow regions, as well as a visual map of the blood flow in the retina.”